Exiqon Expects Initial Data from Blood-Based Colon Cancer Dx in Early 2010 | GenomeWeb

Exiqon this week said it expects initial results from a Danish National Technology Foundation-funded effort to develop a microRNA-based blood diagnostic for colon cancer in the first quarter of 2010.

The disclosure came as part of the company’s announcement of its financial results for the first half of 2009, which included a roughly 32 percent rise in revenues and a 28 percent jump in net losses.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.